CardioRenal Effects of SGLT2 Inhibition in Kidney Transplant Recipients

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
CREST-KT is a single-center, double-blinded, randomized trial of empagliflozin therapy in 72 kidney transplant recipients with (n=36) and without type 2 diabetes (n=36). After evenly dividing patients by type 2 diabetes diagnosis, patients will be randomized 2:1 to empagliflozin 10mg versus placebo.
Epistemonikos ID: 63583ed420c9793168b69fb6adbad6fccefebd3e
First added on: May 08, 2024